Income statement, balance sheet and cash flow statement for the last 8 fiscal years, taken from the XBRL data Benitec Biopharma Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Revenue
12.2
0.1
0.06
0.07
0.08
0
Research and development
4.57
3
7.02
11.3
12.8
15.6
18.3
23.4
General and administrative
4.61
5.57
6.51
6.65
6.38
6.99
23.4
27.8
Operating expenses
9.62
8.38
13.7
17.9
19.2
22.5
41.8
51.2
Operating income
2.58
-8.28
-13.6
-17.9
-19.1
-22.5
-41.8
-51.2
Other non-operating income
0.03
0.01
-0.29
-0.35
-0.48
0.74
3.85
5.65
Pre-tax income
0.17
-0.3
7.91
-17.4
-19
-21
-37.2
-45.3
Income tax
0
Net income
2.61
-8.27
-13.9
-18.2
-19.6
-21.8
-37.9
-45.5
EBITDA
2.74
-8.09
-13.4
-17.7
-18.9
-22.4
-41.7
-51.1
EPS, basic
11.47
-30.46
-12.15
-8.39
-3.13
-1.22
-1.05
-0.98
EPS, diluted
11.47
-30.46
-12.15
-8.39
-3.13
-1.22
-1.05
-0.98
Shares, basic (weighted)
0.23
0.27
1.14
2.17
6.26
18.4
36.2
46.6
Shares, diluted (weighted)
0.23
0.27
1.14
2.17
6.26
18.4
36.2
46.6
Balance sheet
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Cash and equivalents
15.7
9.8
19.8
4.06
2.48
50.9
97.7
180
Other current assets
0.5
0.95
0.8
0.74
1.18
0.52
0.63
1.6
Total current assets
18.8
10.8
20.6
4.82
3.73
51.7
98.5
182
Property, plant and equipment
0.47
0.37
0.38
0.22
0.09
0.18
0.13
0.18
Lease right-of-use assets
0.4
0.77
0.77
0.53
0.27
0.86
0.69
Other non-current assets
0.19
0.14
0.1
0.06
0.03
0.01
Total assets
19.2
11.6
21.4
5.97
4.46
52.2
99.6
183
Accounts payable
1.47
0.28
0.27
0.42
1.14
1.35
0.2
0.91
Accrued liabilities
0.15
0.2
0.28
0.4
0.47
0.48
0.43
0.55
Total current liabilities
2.64
1.14
1.37
2.53
3.98
4.92
1.8
5.34
Lease liabilities
0.21
0
0.56
0.28
0
0.5
0.27
Total liabilities
2.64
1.35
1.37
3.09
4.26
4.96
2.3
5.61
Paid-in capital
127
129
152
152
169
238
326
452
Retained earnings
-109
-117
-130
-148
-168
-190
-228
-274
Other comprehensive income
-1.86
-1.95
-1.46
-1.25
-0.83
-0.89
-0.84
-0.96
Shareholders' equity
16.6
10.2
20
2.88
0.2
47.2
97.3
177
Total equity
16.6
10.2
20
2.88
0.2
47.2
97.3
177
Total liabilities and equity
19.2
11.6
21.4
5.97
4.46
52.2
99.6
183
Shares outstanding
0.23
0.29
2.17
2.17
7.55
10.1
26.3
34.4
Cash flow statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Net income
2.61
-8.27
-13.9
-18.2
-19.6
-21.8
-37.9
-45.5
Depreciation and amortization
0.16
0.19
0.23
0.17
0.14
0.09
0.07
0.06
Stock-based compensation
0.67
0.24
0.63
0.87
0.45
0.83
17.4
26.4
Cash from operations
4.79
-7.54
-12.8
-15.9
-18
-19.4
-23.6
-16.5
Capital expenditures
-0.4
-0.1
-0.22
-0.01
-0
-0.18
-0.02
-0.11
Cash from investing
-0.4
-0.09
-0.22
-0.01
-0
-0.18
-0.02
-0.11
Stock issued
2.25
25.8
17.9
30.5
104
Cash from financing
1.77
22.5
16
68
70.5
99
Exchange rate effect
-0.55
-0.06
0.5
Net change in cash
9.97
-15.7
-1.59
48.4
46.9
82.2
Free cash flow
4.39
-7.63
-13.1
-15.9
-18
-19.6
-23.6
-16.6
Key metrics
Worked out from the statements above. Latest values use fiscal 2026. Valuation uses the share price of $9.59 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-33.2%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-32.3%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
81.9%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
856.9%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
54.7%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
83.4%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
244.6%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
53.6%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
28.6%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
95.2%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
109.9%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
34.0x
Current assets / current liabilities.
Quick ratio
33.7x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
33.7x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$0.98
Net income per basic share, as reported (split-adjusted).
FCF per share
-$0.36
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.35
Cash from operations / diluted weighted shares.
Book value per share
$5.14
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
1.86x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.86x
Market cap / tangible book value, when positive.
FCF yield
-5.0%
Free cash flow / market cap.
Earnings yield
-13.8%
Net income / market cap (the inverse of P/E).
Was Benitec Biopharma Inc. profitable in fiscal 2026?
No. It reported a net loss of $45.5M.
How much free cash flow did Benitec Biopharma Inc. generate in fiscal 2026?
Cash from operations of $16.5M minus capital expenditures of $105.0K left free cash flow of -$16.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.